Zynerba Pharmaceuticals Announces New FAB-C Phase 2 Open-Label Data in Patients with Fragile X Syndrome
12. Juli 2018 07:30 ET
|
Zynerba Pharmaceuticals, Inc.
- Significant Improvements in Behavioral Symptoms Observed in Patients and Sustained through 38 Weeks of Treatment with ZYN002 -- Presentation Today at the 16th NFXF International Fragile X Conference...